Thelansis’s "Multiple Sclerosis (MS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Multiple Sclerosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system, where inflammation damages myelin, axons and neurons. Its course may be relapsing-remitting or progressive. Symptoms vary and include optic neuritis, numbness, weakness, spasticity, balance problems, fatigue and cognitive changes. Disease-modifying therapies (DMTs), from injectables and oral agents to monoclonal antibodies, reduce relapses and inflammatory activity; some slow disability progression. However, progression may persist despite relapse control, and established neurological damage may be irreversible. Research targets Bruton tyrosine kinase (BTK), neuroprotection and remyelination. Tolebrutinib (Cenrifki) received EU authorisation in June 2026 for adults with secondary progressive MS without relapses for two years. Remibrutinib reported positive Phase III results in relapsing MS in October 2026 but is not yet approved for MS. Restoring damaged neural tissue remains a major unmet need.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Multiple Sclerosis (MS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Multiple Sclerosis (MS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.